Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLY 379268 disodium salt is a sodium salt of LY 379268 (Cat. No. 2453), a highly selective group II mGlu receptor agonist.
M. Wt | 231.11 |
Formula | C7H7NNa2O5 |
Storage | Desiccate at RT |
Purity | ≥98% (HPLC) |
PubChem ID | 10197984 |
InChI Key | YASVRZWVUGJELU-MDASVERJSA-N |
Smiles | [H][C@]12[C@]([C@H]2[C@](O[Na])=O)([H])[C@@]([C@](O[Na])=O)(N)CO1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 23.11 | 100 |
The following data is based on the product molecular weight 231.11. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 4.33 mL | 21.63 mL | 43.27 mL |
5 mM | 0.87 mL | 4.33 mL | 8.65 mL |
10 mM | 0.43 mL | 2.16 mL | 4.33 mL |
50 mM | 0.09 mL | 0.43 mL | 0.87 mL |
References are publications that support the biological activity of the product.
Bond et al (1999) LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal cerebral ischaemia. Neurosci.Lett. 273 PMID: 10515191
Bond et al (2000) Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanisms of action in vivo. J.Pharmacol.Exp.Ther. 294 800 PMID: 10945827
Collado et al (2002) (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 agonist with anxiolytic properties. J.Med.Chem. 45 3619 PMID: 12166935
If you know of a relevant reference for LY 379268 disodium salt, please let us know.
View all Glutamate (Metabotropic) Group II Receptor Agonists
Keywords: LY 379268 disodium salt, LY 379268 disodium salt supplier, LY379268, disodium, salt, 2Na, selective, group, II, agonists, Group, Receptors, mGlu2, mGluR2, mGlu3, mGluR3, Glutamate, Metabotropic, (Metabotropic), 5064, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for LY 379268 disodium salt include:
Craig W et al (2021) Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus. Biol Psychiatry 90 385-398 PMID: 33965197
Javier et al (2020) Site-Specific Incorporation of Genetically Encoded Photo-Crosslinkers Locates the Heteromeric Interface of a GPCR Complex in Living Cells. Cell Chem Biol 27 1308-1317.e4 PMID: 32726588
Do you know of a great paper that uses LY 379268 disodium salt from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review LY 379268 disodium salt and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.